LOCALLY RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Clinical trials for LOCALLY RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LOCALLY RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for LOCALLY RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to shrink tumors in Hard-to-Treat cancers
Disease control Recruiting nowThis study tests two drugs, cabozantinib and nivolumab, in people with advanced melanoma or head and neck cancer that has spread. The goal is to see if the combination can shrink or stabilize tumors, and whether certain biomarkers in the tumor can predict who responds best. About…
Matched conditions: LOCALLY RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
New combo therapy aims to improve survival in recurrent head and neck cancer
Disease control Recruiting nowThis study tests whether adding chemotherapy or a chemo-immunotherapy combination before salvage surgery can improve outcomes for people with head and neck cancer that has returned or persisted. About 180 participants with PD-L1 positive tumors will receive either standard surger…
Matched conditions: LOCALLY RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 10, 2026 13:27 UTC
-
Drug combo before surgery may tame returning mouth cancer
Disease control Recruiting nowThis study tests whether giving two drugs (cemiplimab and cetuximab) before salvage surgery can help control recurrent oral cavity squamous cell carcinoma. About 17 adults whose cancer returned at least 3 months after initial treatment will receive the drug combination, then unde…
Matched conditions: LOCALLY RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 12:00 UTC